Verona Pharma (NASDAQ:TARA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
This is a breakdown of current ratings for Verona Pharma and INmune Bio, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Verona Pharma and INmune Bio’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Verona Pharma||N/A||N/A||-$14.99 million||N/A||N/A|
|INmune Bio||N/A||N/A||-$7.68 million||($0.75)||-8.07|
Insider and Institutional Ownership
3.0% of INmune Bio shares are owned by institutional investors. 45.7% of Verona Pharma shares are owned by company insiders. Comparatively, 67.7% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Verona Pharma and INmune Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Verona Pharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.
INmune Bio beats Verona Pharma on 8 of the 8 factors compared between the two stocks.
Verona Pharma Company Profile
ArTara Therapeutics, Inc. develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.
INmune Bio Company Profile
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.